NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products
Rhea-AI Summary
NEXGEL (NASDAQ: NXGL) announced terms to license and acquire a portfolio of six commercial-stage regenerative biomaterial products from Celularity (NASDAQ: CELU).
Key terms: $15 million upfront cash plus up to $20 million in milestone payments tied to net sales. The company says the deal should roughly triple revenue to ~ $35 million and make NEXGEL immediately profitable upon closing. The portfolio targets tendon repair, skin grafts, and bone growth, includes decade-long clinical use and reimbursement pathways, adds commercial/scientific staff, and remains subject to customary closing and financing.
Positive
- Upfront payment of $15 million to acquire portfolio
- Potential milestones up to $20 million tied to net sales
- Revenue expected to triple to about $35 million
- Immediate profitability projected upon closing
- Six commercial-stage products with decade-plus clinical use
Negative
- Transaction is subject to customary closing and financing, creating execution and funding risk
- Milestone payments of up to $20 million are contingent on future net sales and not guaranteed
News Market Reaction – NXGL
In the Mar 12 session, NXGL gained 16.21%, reflecting a significant positive market reaction. Argus tracked a peak move of +42.2% during that session. Argus tracked a trough of -15.3% from its starting point during tracking. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Acquisition Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Biomaterials acquisition deal | Positive | -15.8% | Signed definitive agreement to acquire six Celularity regenerative biomaterial products. |
| Feb 10 | Acquisition financing | Positive | +2.3% | Announced $1.797M financing and potential $14.869M for targeted acquisition. |
| May 16 | Beauty brand acquisition | Positive | +2.7% | Acquired Silly George beauty brand, expected to add $2M in annual revenue. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Acquisition announcements have produced uneven reactions: one large negative move and two modest gains, indicating market caution toward NXGL’s deal-making.
Over the past year, NEXGEL has used acquisitions to expand from consumer beauty into regenerative biomaterials. The May 16, 2024 Silly George acquisition added about $2 million in revenue. In February 2026, NXGL secured $1.797 million of financing tied to an acquisition, followed by the March 10, 2026 definitive agreement for Celularity’s six-product biomaterials portfolio. Today’s consideration terms refine that same acquisition path, detailing upfront and milestone payments for the Celularity portfolio.
Key Terms
milestone payments financial
net sales financial
regenerative biomaterial products medical
clinical use medical
insurance reimbursement financial
Form 8-K regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Consideration for portfolio will consist of a
Transaction expected to approximately triple NEXGEL’s annual revenue to about
LANGHORNE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the consideration terms of its previously announced agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity Inc. (“Celularity”) (NASDAQ: CELU), a regenerative and cellular medicine company.
Consideration for the portfolio will include a
The transaction represents the most significant milestone in the Company’s history and is expected to approximately triple NEXGEL’s revenue base and expected to make the Company profitable immediately upon closing.
The existing portfolio of 6 products encompasses a diversified suite of established regenerative biomaterial products and technologies focused on tendon repair, skin grafts, and bone growth—all within the rapidly growing regenerative biomaterials market. These products carry over a decade of clinical use, demonstrated clinical utility, and existing insurance reimbursement pathways. Critically, the transaction is expected to bring an experienced commercial and scientific team to NEXGEL, meaningfully expanding the Company’s capabilities and reach in the medical technology sector.
The transaction is subject to customary closing processes and financing. A Current Report on Form 8-K containing further details regarding the contemplated transaction was be filed by NEXGEL on March 10, 2026 and is available on the U.S. Securities and Exchange Commission’s EDGAR website.
Adam Levy, CEO of NEXGEL, commented, “This is a transformative moment for our company. In consideration for the portfolio, NEXGEL will pay an upfront cash payment of
About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our expectation that the transaction will approximately triple our revenue and make the Company immediately profitable upon closing, and our expectation the transaction will bring an experienced commercial and scientific team to NEXGEL which will meaningfully expand the Company’s capabilities and reach in the medical technology sector, and our belief this transaction represents a transformative step in its strategy to create shareholder value. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com
